Verve Therapeutics lands $94m Series B

Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has closed $94 million in Series B financing.

Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has closed $94 million in Series B financing. Wellington Management Company and Casdin Capital led the round.

Source: Press Release